CDMOs need to consistently demonstrate agility as demand increases for newly developed therapeutic modalities.
James Park
Advertisement
James Park is executive vice-president and managing director of the Global Sales Center at Samsung Biologics.
Articles by James Park
Advertisement
Latest Updated Articles
Preparing for the Future: Expanding Capacity and Facilitating Multi-modalitiesPublished: May 15th 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
